The rollout of updated Covid vaccines for healthy children and adults this fall is likely to be delayed after the FDA said it will require another clinical trial.

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) has officially approved a COVID-19 vaccine from Novavax for adults 65 and older and for individuals ages 12 to 64 who have an underlying health condition that puts them at higher risk for serious illness from a coronavirus infection.

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy.

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the results of a phase 3 clinical trial published Wednesday in the Journal of the American Medical Association.

Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID-19 vaccine boosters.

It’s hard to believe Moderna (MRNA)once had a market cap exceeding $204 billion. That was in August 2021 at or near the height of the COVID-19 pandemic. As a result of Moderna possessing one of the leading global vaccines to beat back the virus,

Moderna's stock crash may be overdone. Discover why its pipeline, mRNA/AI prospects, and strong balance sheet signal long-term rebound potential.